AMLX Amylyx Pharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage pharma developing novel therapies for endocrine and neurodegenerative diseases with mechanistic rationale and biomarker-driven pipeline
• • New products: Advanced Phase 3 trial for avexitide in PBH; initiated Phase 1 trial for AMX0114 in ALS and selected AMX0318 for long-acting GLP-1 antagonist development
• • Strategic shift: Acquired avexitide patent portfolio in July 2024, expanding IP estate significantly; emphasis on broader rare disease indications including Wolfram syndrome and ALS
• • Quantitative metric: Patent estate grew to 23 U.S. and 257 foreign issued patents plus 130+ pending applications as of Dec 31, 2025; 75 participants enrolled in Phase 3 LUCIDITY trial
• • Noteworthy fact: Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome showing sustained pancreatic beta cell function improvement through 48 weeks

Risk Factors

• • Cybersecurity risk oversight by board and executive team with escalation for material incidents to audit committee
• • Dependence on Senior Director of ISGA with CISSP and 20+ years experience for daily information security strategy
• • Reliance on external vendors for managed network support and security operations creating supply chain cybersecurity risk

Management Discussion & Analysis

• • Revenue $0 in 2025 vs $87.4M in 2024, 100% decline due to discontinuation of RELYVRIO®/ALBRIOZA™ product sales
• • Operating loss $153.3M in 2025 vs $314.7M in 2024, a 51% improvement; R&D expenses down 13% to $90.4M; SG&A down 45% to $62.9M
• • Best performing segment: Avexitide R&D up 771% to $24.1M; worst: AMX0035-ALS R&D down 95% to $1.8M
• • Cash from financing $257.0M in 2025 led by two equity offerings raising approx. $256.2M net; operating cash burn $123.3M; cash & equivalents $317.0M at year-end
• • Management expects R&D and G&A expenses to increase as clinical programs advance; key risks include clinical trial outcomes, regulatory approvals, and capital access

What are the latest AMLX SEC filings in 2026?

Amylyx Pharmaceuticals, Inc. (AMLX) has filed a 10-K annual report on March 3, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AMLX file its most recent 10-K annual report?

Amylyx Pharmaceuticals, Inc. (AMLX) filed its most recent 10-K annual report on March 3, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AMLX 10-Q quarterly reports?

Amylyx Pharmaceuticals, Inc. (AMLX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every AMLX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AMLX filed recently?

Amylyx Pharmaceuticals, Inc. (AMLX)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AMLX insider trading activity (Form 4)?

SignalX aggregates every AMLX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AMLX file with the SEC?

Amylyx Pharmaceuticals, Inc. (AMLX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AMLX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Amylyx Pharmaceuticals, Inc. (AMLX).

What is AMLX's SEC CIK number?

Amylyx Pharmaceuticals, Inc. (AMLX)'s SEC CIK (Central Index Key) number is 1658551. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1658551 to look up all AMLX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AMLX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Amylyx Pharmaceuticals, Inc. (AMLX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.